343 related articles for article (PubMed ID: 17948916)
1. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
[TBL] [Abstract][Full Text] [Related]
2. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
3. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
[TBL] [Abstract][Full Text] [Related]
4. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
9. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
10. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
[TBL] [Abstract][Full Text] [Related]
11. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
12. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
13. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
15. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
16. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
17. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
18. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
19. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
